# Abul Kalam Azad

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 39 papers | 1,254 citations | 516710 16 h-index | 361022 35 g-index |
| 40 all docs | 40 docs citations | 40 times ranked | 2549 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Ameloblastoma with adenoid features: Case report with cytoâ€histopathologic correlation and molecular findings. Diagnostic Cytopathology, 2022, 50, . | 1.0 | 3 |
| 2 | A Splice Site Mutation Associated with Congenital CD59 Deficiency. Hematology Reports, 2022, 14, 172-178. | 0.8 | 0 |
| 3 | Enhanced Carrier Screening for Spinal Muscular Atrophy: Detection of Silent (SMN1: 2 + 0) Carriers Utilizing a Novel TaqMan Genotyping Method. Laboratory Medicine, 2020, 51, 408-415. | 1.2 | 4 |
| 4 | De novo mosaic and partial monosomy of chromosome 21 in a case with superior vena cava duplication. Molecular Cytogenetics, 2020, 13, 45. | 0.9 | 0 |
| 5 | Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castrationâ€resistant prostate cancer models. International Journal of Cancer, 2018, 142, 2163-2174. | 5.1 | 39 |
| 6 | Targeting the MYCNâ€“PARPâ€“DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2018, 24, 696-707. | 7.0 | 80 |
| 7 | Validation of micro<scp>RNA</scp> pathway polymorphisms in esophageal adenocarcinoma survival. Cancer Medicine, 2017, 6, 361-373. | 2.8 | 11 |
| 8 | Androgen receptor inhibitorâ€“induced â€œBRCAnessâ€•and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Science Signaling, 2017, 10, . | 3.6 | 200 |
| 9 | BRM Promoter Polymorphisms and Survival of Advanced Nonâ€“Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. Clinical Cancer Research, 2017, 23, 2460-2470. | 7.0 | 8 |
| 10 | Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome. Oncotarget, 2017, 8, 28093-28100. | 1.8 | 5 |
| 11 | ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. Cancer Epidemiology, 2016, 41, 50-56. | 1.9 | 7 |
| 12 | A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways. Cancer Epidemiology, 2016, 42, 173-180. | 1.9 | 4 |
| 13 | Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. Cancer Biology and Therapy, 2016, 17, 129-138. | 3.4 | 9 |
| 14 | AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer, 2015, 15, 901. | 2.6 | 22 |
| 15 | Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome. Carcinogenesis, 2015, 36, 956-962. | 2.8 | 7 |
| 16 | Two <scp>BRM</scp> promoter insertion polymorphisms increase the risk of earlyâ€stage upper aerodigestive tract cancers. Cancer Medicine, 2014, 3, 426-433. | 2.8 | 16 |
| 17 | Cancer patientsâ€™ acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. Pharmacogenetics and Genomics, 2014, 24, 348-355. | 1.5 | 29 |
| 18 | A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer, 2014, 84, 289-294. | 2.0 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk. Carcinogenesis, 2013, 34, 1012-1017. | 2.8 | 29 |
| 20 | Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients. International Journal of Cancer, 2013, 132, 2520-2527. | 5.1 | 16 |
| 21 | MicroRNA polymorphisms and esophageal cancer outcome.. Journal of Clinical Oncology, 2013, 31, 32-32. | 1.6 | 1 |
| 22 | Promoter polymorphisms of the SWI/SNF chromatin remodeling complex molecule, BRM, and esophageal adenocarcinoma outcome.. Journal of Clinical Oncology, 2013, 31, 4077-4077. | 1.6 | 1 |
| 23 | Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2013, 31, 11057-11057. | 1.6 | 1 |
| 24 | Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival. Clinical Cancer Research, 2012, 18, 196-206. | 7.0 | 39 |
| 25 | Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis. Clinical Cancer Research, 2012, 18, 4526-4537. | 7.0 | 48 |
| 26 | Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers. Cancer, 2012, 118, 1554-1565. | 4.1 | 15 |
| 27 | Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2012, 30, 7586-7586. | 1.6 | 0 |
| 28 | The effect of two BRM promoter variantsÂon the risk of stage I/II upper aerodigestive tract cancers.. Journal of Clinical Oncology, 2012, 30, 10522-10522. | 1.6 | 3 |
| 29 | Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 1535-1535. | 1.6 | 0 |
| 30 | Cancer patient acceptance, understanding, and willingness to pay for pharmacogenetic testing (PGT).. Journal of Clinical Oncology, 2012, 30, 6005-6005. | 1.6 | 1 |
| 31 | Cancer patientsâ€™ and physiciansâ€™ preferences for decision making regarding pharmacogenomic testing (PGT).. Journal of Clinical Oncology, 2012, 30, 13-13. | 1.6 | 1 |
| 32 | Pharmacogenetic and Germline Prognostic Markers of Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 296-304. | 1.1 | 35 |
| 33 | Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk. Oncogene, 2011, 30, 3295-3304. | 5.9 | 51 |
| 34 | HLA-B*07 is a high risk allele for familial cervical cancer. Asian Pacific Journal of Cancer Prevention, 2011, 12, 2597-600. | 1.2 | 8 |
| 35 | A mutation of the epithelial sodium channel associated with atypical cystic fibrosis increases channel open probability and reduces Na<sup>+</sup> self inhibition. Journal of Physiology, 2010, 588, 1211-1225. | 2.9 | 83 |
| 36 | Functional Characterization of a Partial Loss-of-Function Mutation of the Epithelial Sodium Channel (ENaC) Associated with Atypical Cystic Fibrosis. Cellular Physiology and Biochemistry, 2010, 25, 145-158. | 1.6 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease. Human Mutation, 2009, 30, 1093-1103. | 2.5 | 82 |
| 38 | Genetic Analysis of Rwandan Patients With Cystic Fibrosis-Like Symptoms. Chest, 2009, 135, 1233-1242. | 0.8 | 31 |
| 39 | Chitosan membrane as a wound-healing dressing: Characterization and clinical application. Journal of Biomedical Materials Research Part B, 2004, 69B, 216-222. | 3.1 | 327 |